CYTARABINE KABI 100 mg/ml, solution for injection or infusion bottle, 10 ml
Active ingredients: Cytarabine
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Solution for injection or infusionbottle, 10 mlintraveineuse;sous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- CYTARABINE KABI 100 mg/ml, solution injectable ou pour perfusion
- Pharmaceutical form
- solution pour injection ou pour perfusion
- Route of administration
- intraveineuse;sous-cutanée
- Presentation description
- 1 flacon(s) en verre de 10 ml
- Marketing authorisation holder
- FRESENIUS KABI FRANCE
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 31 Dec 2021
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Prescribed by specialists only
- Hospital use only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69333402CIP75828548CIP133400958285486Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CYTARABINEsolution | 100 mg · 1 ml de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.